(Q48563215)

12 February 2018

title

Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors (English)

1 reference

12 February 2018

1 reference

1 reference

1 reference

7

1 reference

12 February 2018

Enrico Franceschi

object named as

Enrico Franceschi

2

0 references

author name string

Luciano Scopece

1

1 reference

12 February 2018

Giovanna Cavallo

3

1 reference

12 February 2018

Anna Paioli

4

1 reference

12 February 2018

Gabriele Paioli

5

1 reference

12 February 2018

Rosa Conforti

6

1 reference

12 February 2018

Carlotta Berzioli

8

1 reference

12 February 2018

Federica Spagnolli

9

1 reference

12 February 2018

Roberta Degli Esposti

10

1 reference

12 February 2018

Lucio Crinò

11

1 reference

12 February 2018

publication date

28 April 2006

1 reference

12 February 2018

Journal of Neuro-Oncology

published in

1 reference

12 February 2018

volume

79

1 reference

12 February 2018

issue

3

1 reference

12 February 2018

page(s)

299-305

1 reference

12 February 2018

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-006-9144-Y

Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma

21 January 2018

1 reference

12 December 2020

Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma

1 reference

12 December 2020

Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: A clinical study conducted at the Northern Israel Oncology Center

1 reference

12 December 2020

Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Writing Committee for The Brain Tumor Center at Duke

1 reference

12 December 2020

Salvage chemotherapy for oligodendroglioma

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

12 December 2020

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

1 reference

12 December 2020

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

1 reference

12 December 2020

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

1 reference

12 December 2020

Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study.

1 reference

12 December 2020

Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study.

1 reference

12 December 2020

Primary glial tumor patients treated by combining cis-platin and etoposide

1 reference

12 December 2020

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

1 reference

12 December 2020

Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma

1 reference

12 December 2020

Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration

1 reference

12 December 2020

Penetration of etoposide into human malignant brain tumors after intravenous and oral administration

1 reference

12 December 2020

Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study

1 reference

12 December 2020

10.1007/S11060-006-9144-Y

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018